Resource Summary Report

Generated by dkNET on Sep 4, 2026

NBL-S

RRID:CVCL_2136
Type: Cell Line

Proper Citation

RRID:CVCL_2136

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2136

Proper Citation: RRID:CVCL_2136

Description: Cell line NBL-S is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Neuroblastoma

Defining Citation: PMID:11550280, PMID:15892104, PMID:16822308, PMID:18724359, PMID:23202128, PMID:28350380

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NBL-S

Synonyms: NBL_S, NBLS

Cross References: BioSample:SAMN03473469, Cosmic:848930, Cosmic:923829, Cosmic:930070, Cosmic:1019947, Cosmic:1109367, Cosmic:1161997, Cosmic:1167414, Cosmic:1526636, DSMZ:ACC-656, DSMZCellDive:ACC-656, GEO:GSM2371248, GEO:GSM2394377, GEO:GSM4104587, GEO:GSM4104588, GEO:GSM4105328, GEO:GSM4105329, GEO:GSM4105330, GEO:GSM4105331, GEO:GSM4105332, IARC_TP53:23593, Wikidata:Q54907552

ID: CVCL_2136

Record Creation Time: 20220427T220834+0000

Record Last Update: 20260904T014721+0000

Ratings and Alerts

No rating or validation information has been found for NBL-S.

No alerts have been found for NBL-S.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Pommerenke C, et al. (2026) Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. iScience, 29(7), 116469.

Chaves GS, et al. (2026) Hypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in Neuroblastoma. Clinical and translational science, 19(3), e70508.

Lindsay J, et al. (2026) Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma. Molecular cancer therapeutics, 25(4), 635.

Hollander JF, et al. (2025) Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. Cancer research communications, 5(1), 167.

Montuori G, et al. (2025) Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. Cancer discovery, 15(10), 2054.

Graham MK, et al. (2024) The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres. Cancer research communications, 4(6), 1533.

Kaufman ME, et al. (2024) Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures. Cancer research communications, 4(8), 2255.

Raman S, et al. (2021) A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. Cell reports. Medicine, 2(7), 100344.

Buongervino S, et al. (2021) Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. Molecular cancer therapeutics, 20(11), 2228.

Morita K, et al. (2020) Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2. Cell, 181(3), 702.

Jung M, et al. (2020) ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer. International journal of cancer, 147(8), 2225.